SSB and Südpack Medica AG Sign Exclusive Cooperation Agreement
News Jun 17, 2011
Sartorius Stedim Biotech (SSB), and Südpack Medica AG, have signed an exclusive cooperation agreement on the development, manufacture and supply of polymer plastic films for the biopharmaceutical market.
As part of this strategic partnership, which is based on an initial term of ten years, Südpack will produce plastic film materials for SSB to be employed in the manufacture of single-use bags and systems. These single-use bags are primarily utilized by customers in the pharmaceutical industry for cell cultivation, transportation and storage of biopharmaceutical liquids.
Moreover, SSB and Südpack will collaborate on the development of novel multi-layer films with improved product characteristics, which are to be employed in single-use bioreactors, for instance. The first product innovations from this cooperation are expected in approximately one year from now.
“Südpack Medica AG has already been developing and manufacturing packaging solutions for medical product manufacturers for many years. Cooperation with Sartorius Stedim Biotech is now an important step into the new, promising markets of the future. We are proud that Sartorius Stedim Biotech, one of the market leaders in the biotechnology industry, has selected us as a partner to jointly develop innovative film laminates. This also tells me that we are on the right track with our strategy of continuously investing in new technologies and developments,” commented Johannes Remmele, Managing Director of Südpack, upon signing the agreement.
“Through the alliance with Südpack, we have gained an excellent partner for the development and manufacture of complex multi-layer films that we process in the production of our single-use bags. By supplying innovative single-use products, we are striving to continue offering our customers real added value in the future as well. For this reason, the strategic partnership with Südpack represents a key step for us,” said Dr. Oscar-Werner Reif, Executive Vice President of Research and Development at Sartorius Stedim Biotech.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
Partnering with IDNs BioPharma Strategy Summit West
Mar 20 - Mar 21, 2019
International Conference on Hepatology and Liver Diseases
Jun 10 - Jun 11, 2019